Ongoing treatment(s)-Biological therapy-Immunomodulator(s) Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological therapy-Immunomodulator(s) Posts on Medivizor

Lenalidomide consolidation therapy for patients receiving chemoimmunotherapy for chronic lymphocytic leukemia

Posted by on Sep 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of lenalidomide consolidation therapy after chemoimmunotherapy for patients with chronic lymphocytic leukemia. This study concluded that this regimen improves outcomes for these patients. Some background Fludarabine (Fludara) is a chemotherapy used for the treatment of chronic lymphocytic...

Read More

Inside the First FDA-Approved CAR-T Cell Therapy

Posted by on Nov 8, 2017 in Leukemia | 0 comments

Video Information: The first CAR T-cell therapy to receive FDA approval, CTL019 (Kymriah) was recently approved for children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Expert Dr. Michael Deinginger joins Patient Power Founder Andrew Schorr to explain CAR T-cell...

Read More

What new developments have been made in immunotherapy for acute myeloid leukaemia?

Posted by on Oct 14, 2017 in Leukemia | 0 comments

In a nutshell This article aimed to review the latest developments in immunotherapy treatments for acute myeloid leukemia. This article concluded that the development of immunotherapies for acute myeloid leukemia is lagging behind that of other cancers. Some background Standard treatments for acute myeloid leukemia (AML) include chemotherapy,...

Read More

Inhibitor Therapies: How Do They Treat CLL?

Posted by on Oct 7, 2017 in Leukemia | 0 comments

Video information: Treatments that inhibit CLL, such as BTK Inhibitors, are becoming more commonly used in patients. So, how do they work? CLL expert Dr. John Burke explains the mechanism of action that inhibitor therapies use to treat CLL. Dr. Burke also discusses how inhibitors affect cancer proteins and how they differ from...

Read More